FOXM1 and neoplasm: The in vivo response to treatment in the primary tumors fit the proposed dependence on FOXM1 levels (i.e., PDX1 with low FOXM1 responded similarly to paclitaxel alone or combination treatment with ICG-001, while the MDA-MB-468 xenograft and PDX2 with higher levels of FOXM1 showed the greatest reduction in tumor growth by combination treatment with paclitaxel plus ICG-001).